Radius Health Inc (NASDAQ:RDUS) was down 7% on Monday . The stock traded as low as $19.54 and last traded at $19.60. Approximately 714,097 shares traded hands during mid-day trading, an increase of 20% from the average daily volume of 592,971 shares. The stock had previously closed at $21.07.
Several equities research analysts have recently weighed in on RDUS shares. HC Wainwright started coverage on shares of Radius Health in a research note on Thursday, February 14th. They issued a “neutral” rating and a $22.00 target price on the stock. BidaskClub raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Tuesday, January 22nd. Zacks Investment Research raised shares of Radius Health from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Monday, May 6th. Cowen reissued a “hold” rating on shares of Radius Health in a research note on Wednesday, May 8th. Finally, ValuEngine raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. Radius Health presently has an average rating of “Hold” and a consensus price target of $38.00.
The company has a market cap of $936.49 million, a price-to-earnings ratio of -4.02 and a beta of 0.98. The company has a current ratio of 5.16, a quick ratio of 5.04 and a debt-to-equity ratio of 6.75.
In related news, Director Willard H. Dere sold 1,680 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $22.22, for a total value of $37,329.60. Following the transaction, the director now owns 8,620 shares of the company’s stock, valued at approximately $191,536.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jessica Hopfield purchased 12,800 shares of Radius Health stock in a transaction that occurred on Tuesday, March 5th. The stock was bought at an average cost of $19.23 per share, for a total transaction of $246,144.00. Following the purchase, the director now directly owns 12,800 shares in the company, valued at $246,144. The disclosure for this purchase can be found here. Corporate insiders own 4.00% of the company’s stock.
A number of hedge funds have recently bought and sold shares of RDUS. MetLife Investment Advisors LLC increased its stake in Radius Health by 56.4% in the 3rd quarter. MetLife Investment Advisors LLC now owns 27,474 shares of the biopharmaceutical company’s stock worth $489,000 after buying an additional 9,912 shares during the period. Vanguard Group Inc. increased its position in Radius Health by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 3,571,571 shares of the biopharmaceutical company’s stock valued at $63,574,000 after purchasing an additional 53,281 shares during the period. Vanguard Group Inc increased its position in Radius Health by 1.5% during the 3rd quarter. Vanguard Group Inc now owns 3,571,571 shares of the biopharmaceutical company’s stock valued at $63,574,000 after purchasing an additional 53,281 shares during the period. Virtu Financial LLC purchased a new position in Radius Health during the 4th quarter valued at about $205,000. Finally, Bank of Montreal Can increased its position in Radius Health by 231.3% during the 4th quarter. Bank of Montreal Can now owns 1,544 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 1,078 shares during the period.
About Radius Health (NASDAQ:RDUS)
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
See Also: Call Option Volume
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.